Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Phase 2TerminatedNCT03883386

University of Michigan3 enrolled

Overview

G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

Conditions

Bone Pain

Interventions

LoratadineDRUG

10 mg in a capsule

PlaceboDRUG

Administered via capsule

Eligibility

Sex: ALLMin age: 12 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of neutropenia * Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4 times per month * Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain Inventory (BPI) Exclusion Criteria: * Other sources of chronic pain * Previously tried loratadine for 7 consecutive days or more for bone pain * Allergy to loratadine * Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication

Locations (1)

The University of Michigan

Ann Arbor, Michigan, United States

Outcomes

Primary Outcomes

Change in Pain Severity Scores as Measured by the Brief Pain Inventory (BPI)

The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. The questions ask participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." Modified BPI: Included the pain intensity subscale, it is a Numerical Rating Scale with 4 questions (3-6): each item is ranked where 0 is no pain - 10 the worst pain. The Modified BPI will be measured on Days 2, 4, and 6. The full BPI will be measured on Day 7. On day 7 only responses from questions 3-6 will be analyzed for this outcome and a mean composite score for Days 2, 4, 6, and 7 will be calculated.

Time frame: Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).

Secondary Outcomes

Change in Pain Interference in Patients as Measured by the Brief Pain Inventory (BPI)

Brief Pain Inventory (BPI) asks the participant to rate how their pain interferes with daily activities where "0" indicates "does not interfere and "10" indicates "completely interferes". The Pain Intensity Scale scores (Numerical Rating Scale (NRS)) for 7 questions: general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life from (BPI question 9A-G); 0 no life interference - 10 complete interference. Pain interference will be assessed on day 7 of each week.

Time frame: Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.